Market Newsdesk

SAN JOSE, Calif., Nov. 19, 2020 /PRNewswire/ — PayPal Holdings, Inc. (NASDAQ: PYPL) today announced enhancements to its Giving platform, to provide customers with a new way to directly connect with millions of people who can help them raise money on behalf of a cause close to their heart, and allow those who can help to give what they can this holiday season. Inspired by the rising popularity of peer-to-peer crowdfunding accelerated by the global pandemic, PayPal will now enable its customers in the U.S. to create customized fundraising campaigns for themselves, their community or their cause through the Generosity Network, to raise up to $20,000 over a 30-day period.

More than half of charitable organizations in the U.S. expect to raise less money than they did in 2019, as a result of the financial strain experienced by people and businesses across the country since the start of the pandemic.¹ With more than 65 million Americans filing for unemployment over the course of the pandemic,² many have turned to family, friends, and the generosity of those in their community who have been able to provide support. Now, with the Generosity Network, PayPal is providing a new way to seamlessly connect those who need a helping hand with millions of others who can give back and offer their support.

“From collecting money for grocery deliveries to high-risk populations to fundraising campaigns in support of teachers and frontline workers, we’ve seen an outpouring of generosity from the PayPal community using our platform to help one another during this unprecedented year,” said Oktay Dogramaci, VP, Giving, PayPal. “The Generosity Network was designed to provide an accessible, easy and secure way for our customers to raise money on behalf of causes, and connect them with millions of PayPal customers who can offer their support this holiday season and beyond.”

Generosity Network campaigns can be created in just a few simple steps from the PayPal website. Donations are deposited directly into the organizer’s account with PayPal, allowing them to easily distribute the funds to their intended cause – be it a small business, charitable organization, friend, family member or even themselves.

All the ways to give

 
There are many ways to give through PayPal on #GivingTuesday and throughout the holiday season, and no amount is too small. Below are a few more ways to give with PayPal, whether you have $5 or $500 to donate this year.

• Donate while you shop: As you shop online for gifts for your loved ones, look for the option to add a $1 donation to charity before you complete your purchase with PayPal. You can set your favorite charity in your PayPal Account Overview online or in-app, or PayPal will suggest a relevant charity for you at checkout. These microdonations add up to real impact – shoppers have donated more than $10M at checkout since the feature launched last year.
• Donate your credit card rewards: PayPal has expanded its Pay with Rewards feature to enable customers with eligible credit cards from Chase, American Express, Citi, Discover and Capital One to donate their rewards in support of thousands of charities enrolled with PayPal Giving Fund. Rewards balances will automatically be converted to an equivalent dollar donation amount.
• Always-On Giving, 100% Donated to Charity – On PayPal.com and in the PayPal app, you can donate to support thousands of charities with PayPal Giving Fund, without any deductions or transaction fees.

For more information, go to: https://www.paypal.com/generosity-network/.

About PayPal
PayPal has remained at the forefront of the digital payment revolution for more than 20 years. By leveraging technology to make financial services and commerce more convenient, affordable, and secure, the PayPal platform is empowering more than 350 million consumers and merchants in more than 200 markets to join and thrive in the global economy. For more information, visit paypal.com.

Media Relations Contact

Jaymie Sinlao


[email protected]
 

¹ According to a 2020 survey conducted by the Association of Fundraising Professionals.
² According to data released by the Department of Labor.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/paypal-launches-enhanced-giving-platform-to-put-the-power-of-fundraising-in-customers-hands-this-holiday-301176917.html

SOURCE PayPal, Inc.

LISHUI, China, Nov. 19, 2020 /PRNewswire/ — Lixiang Education Holding Co., Ltd. (the “Company” or NASDAQ: LXEH), a prestigious private primary and secondary education service provider in China, today announced its unaudited financial results for the third quarter of 2020.

Initial Public Offering (“IPO”)

On October 1, 2020, the Company announced the pricing of its IPO of 3,333,400 American Depositary Shares (“ADS”), each ADS representing five of its ordinary shares, at a price of US$9.25 per ADS for a total offering size of approximately US$30.8 million. The Company subsequently commenced trading on the NASDAQ Exchange under the symbol “LXEH.” AMTD Global Markets Limited and Loop Capital Markets LLC acted as joint bookrunners of the offering and as the representatives of the underwriters. The closing date of the IPO was October 5, 2020.

Third Fiscal Quarter Ended September 30, 2020 Financial Highlights

• The number of total students has increased by 297 or 6.5% for the semester commenced in September 2020, compared with semester commenced in September 2019. In particular, the number of students in Yijing Campus-Featured Division increased from 184 to 362, an increase of 96.7%.
• Net revenues for the three months ended September 30, 2020, were RMB19.93 million, a slight increase of RMB0.45 million compared with RMB19.48 million for the three months ended September 30, 2019.
• Cost of revenues for the three months ended September 30, 2020 increased by RMB2.01 million or 9.3% to RMB23.60 million from RMB21.58 million for the same period last year due to the increasing labor cost.
• Net loss was RMB3.33 million for the three months ended September 30, 2020, a decrease of 38.0% or RMB2.03 million from the same period last year, and the decrease was partially due to the incremental RMB5.05 million of government subsidies received and recognized during the third quarter this year.

Mr. Wei Biao, CEO of the Company, commented that “In response to the challenges created by the unprecedented COVID-19 pandemic starting from the first quarter this year, we promptly implemented various actions , such as introducing high-quality online education services and maintaining ongoing and effective school-teacher communication , to minimize the negative repercussions brought by COVID-19. We have managed to ensure the quality of teaching amid the pandemic.

Yijing Campus-Featured Division has obtained impressive teaching outcomes by delivering its well-designed featured PRC curriculum. The number of students increased from 184 to 362, representing an increase of 96.7%. Considering the campus utilization rate is below 50% and the campus has a high recognition status, the continued increase in the number of students and tuition are highly foreseeable in the short-term.

Generally, we have maintained the continued growth of income for the past three quarters , and we will continuously enhance the quality of teaching and strengthen the overall competitiveness, which allows us to strengthen our success in both students recruiting and pricing.”

Third Quarter 2020 Financial Results

Net Revenues

Net revenues for the three months ended September 30, 2020 were RMB19.93 million, compared with RMB19.48 million for the three months ended September 30, 2019. The slight increase was contributed by the increase of student numbers and average tuition price per student, offset by the decrease of non-recurring revenues from activities during summer vacation. As the majority of the increase in number of students was in Yijing Campus-Featured Division which had a higher price than Baiyun Campus, the average price per student increased in the third quarter of 2020 accordingly.

Revenues from tuition, meal and accommodation services for the third quarter of 2020 were RMB17.12 million, compared with RMB15.27 million for the same quarter of 2019.

The variation in the revenues was explained by the increase of the student numbers and also the fees charged for meals. The increase in revenues is explained by the increase in number of students, particularly in Yijing Campus-Featured Division, and also the increase in fees charged for meals in Baiyun Campus.

Cost of Revenues

Cost of revenues for the three months ended September 30, 2020 was RMB23.60 million, a 9.3% increase from RMB21.58 million for the three months ended September 30, 2019.

Labor costs for the third quarter of 2020 were RMB16.21 million, compared with RMB15.15 million for the same quarter of 2019. The increase in labor costs was mainly due to the increase in number of teachers in respond to the increase of number of students, particularly in Yijing Campus-Featured Division.

Gross Loss

As a result of the foregoing, gross loss for the third quarter of 2020 was RMB3.67 million, a decrease of RMB1.57 million compared with the gross loss of RMB2.10 million for the same quarter of 2019.

Operating Expenses

Total operating expenses for the third quarter of 2020 were RMB4.28 million, compared with RMB2.58 million for the same quarter of 2019. The increase was mainly due to the professional service fees charged to the general and administrative expenses that were not directly related to the offering of the Company’s ordinary shares in the United States.

Other Income, net

Total net other income for the third quarter of 2020 were RMB5.05 million, compared with RMB0.02 million for the same quarter of 2019. The increase was contributed by the government grants received and recognized in the third quarter of 2020 to support the development of local private schools.

Net Loss

Net loss for the third quarter of 2020 was RMB3.33 million, compared with net loss of RMB5.36 million for the same quarter of 2019.

The net loss incurred in the third quarter was caused by the industry seasonal effect. No revenue from tuition fees, meals or accommodation services is generated in July and August which are the summer vacation in China, but fixed costs still remain. However, the financial results of the fourth quarter will not be affected by this seasonal effect.

Net Loss Attributed to Ordinary Shares

Basic and diluted net loss per share attributable to ordinary shareholders of the Company for the third quarter of 2020 were both RMB0.07, compared with basic and diluted net loss per share of RMB0.11 for the same quarter of 2019.

Basic and diluted net loss per ADS attributable to ADS holders of the Company for the third quarter of 2020 were both RMB0.33, compared with basic and diluted net loss per ADS of RMB0.54 for the same quarter of 2019.

Cash and Working Capital

As of September 30, 2020, the Company had total cash and cash equivalents and short-term investment balances of RMB17.67 million, a decrease of RMB27.06 from RMB44.73 million as of December 31, 2019. The decrease was mainly due to the repayment of bank loans.

Outlook

For the fourth quarter of 2020, the Company currently expects:

• Net revenues to be between RMB50.0 million to RMB55.0 million, which would represent an increase of approximately 4.8% to 15.3% from RMB47.7 million for the same quarter last year;

This forecast reflects the Company’s current and preliminary view on the current business situation and market conditions, which is subject to change.

About Lixiang Education Holding Co., Ltd.

Founded in Lishui City, China, Lixiang Education Holding Co., Ltd. is one of the top 10 private primary and secondary education institutions in Zhejiang Province. The Company’s education philosophy is to guide the healthy development of students and to establish a solid foundation for their lifelong advancement and happiness. For more information, please visit: www.lixiangeh.com.

Exchange Rate Information

This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from Renminbi to U.S. dollars are made at a rate of RMB6.7896 to US$1.00, the rate in effect as of September 30, 2020 published by the Federal Reserve Board.

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. The Company may also make written or oral forward- looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company’s strategies, future business development, and financial condition and results of operations; the expected growth of the Chinese private education market; Chinese governmental policies relating to private educational services and providers of such services; the Company’s ability to maintain and enhance its brand. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:

Siyi Ye

Tel: +86-578-2267142
Email:

[email protected]

 

 

View original content:http://www.prnewswire.com/news-releases/lixiang-education-holding-co-ltd-announces-unaudited-third-quarter-2020-financial-results-301176922.html

SOURCE Lixiang Education Holding Co., Ltd.

HOUSTON, Nov. 19, 2020 /PRNewswire/ — CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced its joint sponsorship with WPD Pharmaceuticals for the 2020 Society of NeuroOncology (SNO) Virtual Meeting held November 19-21, 2020.

CNS and WPD’s joint sponsorship is on the Supporter’ level, which includes a booth in the virtual exhibit hall. Dr. Patrick Wen, Director of Center for Neuro-Oncology at Dana-Farber Cancer Institute and member of CNS Pharmaceuticals’ Science Advisory Board, will be participating in a panel discussion on clinical trials during the plenary session on Friday, November 20, as well as in online poster presentations.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of Feb. 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation.

For more information, please visit www.CNSPharma.com.

About WPD Pharmaceuticals 

WPD is a biotechnology research and development company with a focus on oncology and virology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has licensed in certain countries 10 novel drug candidates with 4 that are in clinical development stage. These drug candidates were researched at medical institutions, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland. 

WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain compounds for about 30 countries, mostly in Europe. Such agreements provide WPD with certain research, development, manufacturing and sales rights and obligations, among other things. 

For more information, please visit wpdpharmaceuticals.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-and-wpd-pharmaceuticals-to-contribute-sponsorship-to-2020-sno-virtual-meeting-301176680.html

SOURCE CNS Pharmaceuticals, Inc.

BOTHELL, Wash., Nov. 19, 2020 /PRNewswire/ — BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced it was ranked number 403 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America. BioLife Solutions’ revenue grew 233% from 2016 through 2019.

Mike Rice, BioLife Solutions CEO, remarked, “We’ve built a class-defining portfolio of cell and gene therapy bioproduction tools. The regenerative medicine space is poised for significant growth over the next several years and BioLife is very well configured to become an even more critical and larger supplier to cell and gene therapy developers.”

About Deloitte’s 2020 Technology Fast 500™
Now in its 26^th year, Deloitte’s Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2016 to 2019.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least $US50,000, and current-year operating revenues of at least $US5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

About BioLife Solutions
BioLife Solutions is a leading supplier of class-defining cell and gene therapy bioproduction tools and services. Our portfolio includes our proprietary CryoStor^® freeze media and HypoThermosol^® shipping and storage media, ThawSTAR^® family of automated, water-free thawing products, evo^® cold chain management system,  Custom Biogenic Systems high capacity storage freezers and SciSafe biologic storage services. For more information, please visit www.biolifesolutions.com, and follow BioLife on Twitter.

Cautions Regarding Forward Looking Statements

Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about the Company’s expectations regarding the profitability and further adoption of the Company’s evo cold chain management platform solution and its relationship with World Courier and Quick International Courier. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including risks and uncertainties related to market conditions, and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Media & Investor Relations

Roderick de Greef

Chief Financial Officer
(425) 686-6002
[email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/biolife-solutions-ranked-403rd-fastest-growing-company-in-north-america-on-deloittes-2020-technology-fast-500-301176641.html

SOURCE BioLife Solutions, Inc.

Canadian Company developing a global platform for healthcare supply security;

Targeting global PPE market with onshore manufacturing model and integrated digital health solutions.

VANCOUVER, BC, Nov. 19, 2020 /PRNewswire/ – Maitri Health Technologies Corp. (“Maitri” or “the Company”) (CSE: MTEC), a global platform for healthcare supply security, announced today that it has received final approval from the Canadian Securities Exchange (the “CSE”) for the Company’s common shares (the “Common Shares”) to commence trading on the CSE at the opening of markets today under the symbol “MTEC”.

Prior to and in connection with the listing of Maitri’s Common Shares on the CSE, the Company’s Listing Application dated November 17, 2020 has been accepted by the CSE and filed on SEDAR under the Company’s profile.

Maitri brings a new business model to the global healthcare supply market. Maitri’s Board of Directors and Strategic Advisors consists of experienced leaders with extensive expertise, including a former Canadian Minister of Health, one of the world’s foremost specialists in infectious diseases, and a globally recognized researcher and innovator in healthcare supply systems.

“We’re more than just a provider of materials,” said Andrew Morton, CEO. “We offer a complete platform of innovative masks, shields, disinfectants and testing solutions that are sourced and manufactured onshore. Our model provides a stable, steady supply of quality, certified products that has often been difficult for organizations to find and secure in the healthcare supply system.”

“Our vision is to integrate technology into all aspects of our healthcare system,” said Mr. Morton. “We see digital solutions as a significant advancement. By layering in technology, our clients can better manage, track, replenish and trace their PPE and the people using them. We intend to create a more sophisticated supply system that enables safer workplaces and helps keep businesses and economies running uninterrupted well beyond the current pandemic.”

Maitri plans to export this model internationally, by licensing or building domestic manufacturing and supply logistics throughout the Americas and across the globe.

About Maitri Health Technologies
Maitri Health Technologies (CSE: MTEC) is a global platform for healthcare supply security. Our mission is to enhance safety and quality of life, and keep organizations and economies running. Maitri provides a reliable source of innovative, certified personal protective equipment (PPE) and testing solutions through an onshore manufacturing model. Our stable, scalable supply chain is integrated with unique digital technology to deliver a comprehensive healthcare supply platform. For more information: https://maitrihealth.ca/

Forward-Looking Statements

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking.  Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements.  There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties.  We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

View original content:http://www.prnewswire.com/news-releases/maitri-health-technologies-announces-commencement-of-trading-on-canadian-securities-exchange-301176682.html

SOURCE Maitri Health Technologies Corp.

SAN DIEGO, Nov. 19, 2020 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the Company has entered into separate, privately negotiated transactions (the “Agreements”) with certain holders of its existing 2.25% Convertible Senior Notes due 2024 (the “2024 Notes”) to repurchase approximately $83 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of an amount of cash estimated to be the sum of (i) approximately $110 million based on the Company’s November 18, 2020 closing stock price of $86.91 per share, (ii) an amount based in part on the daily volume-weighted average prices per share of the Company’s common stock during a five-trading day pricing period following execution of the Agreements and (iii) accrued and unpaid interest. The 2024 Notes repurchases are expected to close on December 2, 2020, subject to customary closing conditions. Such repurchases of the 2024 Notes could affect the market price of the Company’s common stock. 

This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which the offer, solicitation, or sale would be unlawful prior to the registration or qualification thereof under the securities laws of any such state or jurisdiction.

About Neurocrine Biosciences

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The Company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)

Forward-Looking Statements

In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to the amount of 2024 Notes to be repurchased, the timing of completion of the repurchases, and the impact of the repurchases on the market price of the Company’s common stock.  Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are: changes in the price of the Company’s common stock; changes in the convertible note and other capital markets; and other risks described in the Company’s periodic reports filed with the Securities and Exchange Commission, including without limitation the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2020. The Company disclaims any obligation to update the statements contained in this press release after the date hereof.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-repurchase-of-convertible-notes-301176754.html

SOURCE Neurocrine Biosciences, Inc.

SAN MATEO, Calif., Nov. 19, 2020 /PRNewswire/ — Today, Coupa Software (NASDAQ: COUP) published the findings from its Business Spend Index (BSI), Q4 2020 Outlook. The Coupa BSI analyzes billions of dollars of aggregated and anonymized business spend decisions across Coupa’s platform, often serving as an early indicator of macroeconomic health over the next three to six months. The Q4 Outlook shows that business spend sentiment improved over the prior quarter (an increase of 6 percent), but overall confidence is still well below trend.

Following a quarter of modest improvement in corporate spending, the Coupa BSI suggests that businesses are continuing to adjust to the new normal and are beginning to return to pre-COVID spending levels, albeit at a slower rate than in the prior quarter. Though still cautious about the global economic outlook, businesses are spending more in areas related to remote work, such as technology, shipping and freight, and contingent workforce support.

Data from the past quarter shows the following year-over-year changes in business spending:

• 97 percent decrease in business spending on air travel
• 22 percent decrease in business spending on office supplies
• 13.5 percent increase in business spending on technology, including hardware, software, and services
• 41 percent increase in contingent workforce spend
• 29 percent increase in business spending for shipping and freight

“The Coupa BSI Q4 Outlook indicates that business spend sentiment is continuing to recover from its sharp drop in Q1 as companies grow increasingly comfortable operating in the new normal,” said Jeff Collins, chief economist at Coupa. “However, despite the positive adjustments made by companies in most major sectors, our analysis shows that confidence in the economy is still low and is likely to remain below trend for at least the next three to six months.”

What to Expect in the Coming Months

• Businesses Overall: Spend data indicates that overall, business spend sentiment is continuing to increase from its sharp drop in Q1 but is still below the trend line.
• Financial Services: Despite rising default risk, business spend sentiment for financial services improved over the last two quarters and looks set to deliver solid growth for the next three to six months.
• Health and Life Sciences: Spend sentiment for health and life sciences increased significantly since last quarter. The sector likely benefited from the reduction in COVID-19 cases at the end of the summer and the return of elective surgeries.
• High Tech: The impact the pandemic has had on remote work has been largely beneficial for the tech sector, and as a result high tech held a steady increase in business spend sentiment quarter-over-quarter.
• Manufacturing: Spend sentiment for manufacturing continues to decline, and as a result, contribution of the sector to GDP is likely to decline over the next three to six months.
• Retail: Business sentiment in the sector indicates that retail has improved modestly; however, the sector is still below trend likely related to multiple retailers filing for bankruptcy in 2020.

To view the Coupa BSI Q4 2020 Outlook in its entirety, visit www.spendindex.com.

Disclaimer: The findings of the BSI are not necessarily indicative of trends happening with Coupa’s business.

The Coupa BSI Methodology
The Coupa BSI is an early indicator of potential economic growth based on current business spending decisions of hundreds of U.S. companies. It analyzes billions of dollars of anonymized transactions from the Coupa BSM Platform, which has cumulatively processed nearly $2 trillion in business spend, to measure confidence around U.S. economic growth at an aggregate level, as well as an industry level within financial services, health and life sciences, high tech, manufacturing, and retail. The index is based on three key measurements related to business spend: (1) spend volume, (2) average time to approve spend decisions, and (3) average rate of spend approval/rejection.

The Coupa BSI is normalized to a baseline value of 100, which represents the weighted composite value of the three components in the baseline reference period (July 2016). The weighting methodology is periodically updated based on recalibration of the model. This was most recently done for Q4 2020.

About Coupa Software
Coupa empowers companies around the world with the visibility and control they need to spend smarter and safer. To learn more about how Coupa can help you spend smarter, visit www.coupa.com. Read more on the Coupa Blog or follow @Coupa on Twitter.

View original content to download multimedia:http://www.prnewswire.com/news-releases/coupa-business-spend-index-reveals-that-business-spend-sentiment-is-improving-but-remains-below-trend-301176528.html

SOURCE Coupa Software

BEIJING, Nov. 19, 2020 /PRNewswire/ — BOE Technology Group Co., Ltd. (BOE) recently released its 55-inch 4K active-matrix quantum dot light-emitting diode (AMQLED) display, the first of its kind in the world. This marks another milestone the display maker has achieved in the field of electroluminescent quantum dots following the launch of its high-resolution quantum light-emitting diode (QLED) technology at the beginning of this year.

BOE’s 55-inch UHD AMQLED display

Quantum dot technology has made its way into display products including photoluminescent quantum dot-based backlight unit (QD-BLU) and electroluminescent AMQLED. AMQLED displays do not require a backlight; instead, quantum dots can emit light themselves when stimulated by current. AMQLED displays present a variety of advantages such as self-emitting, a wide color gamut, and a long lifetime, representing the development trend of quantum dot displays. Additionally, the R&D of large quantum dot printing technology and products is a focus of attention in the industry.

Through technological innovation, BOE has made major breakthroughs in the uniformity and stability during large-size quantum dot printing. Based on its cutting-edge electroluminescent quantum dot technology, BOE’s first-ever 55-inch 4K AMQLED display features a resolution of 3840×2160, a color gamut of 119% NTSC, and a contrast ratio of 1,000,000:1, having a broad application prospect in the field of large-size displays.

BOE is a world leading player in the field of quantum dot electroluminescent research and development. In 2017 BOE launched 5-inch and 14-inch AMQLED prototypes fabricated by inkjet printing, which won the Best in Show award in 2017 SID Display Week. As a global leader in the semiconductor display industry, BOE keeps close watch on frontier display technologies and is committed to bringing its innovative display products and solutions to myriads of scenarios, thereby delivering the best visual experiences to users.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/boe-unveils-the-worlds-first-55-inch-uhd-amqled-display-301176806.html

SOURCE BOE Technology Group Co., Ltd.

SANTA CLARA, Calif., Nov. 19, 2020 /PRNewswire/ — SVB Financial Group today announced Innovate Next, a new virtual summit on January 7, 2021, convening executives and investors from across the globe to discuss the most pressing topics and innovative solutions transforming healthcare.

The event will be hosted by SVB Financial Group entities Silicon Valley Bank (SVB), healthcare investment bank SVB Leerink, and SPD Silicon Valley Bank (SSVB), SVB’s joint venture bank in China. Together, these three firms’ deep knowledge of the global healthcare and technology industries, financing trends and opportunities for investors will create the essential industry event to kick off the new year.

“We’re thrilled to create a space where the world’s leading voices at the intersection of healthcare and technology can come together to share their knowledge, advice and solutions at a time when collaboration is more important than ever,” said Katherine Andersen, Head of Life Science and Healthcare Relationship Banking at Silicon Valley Bank. “SVB’s extensive network of global life science and healthcare companies and investors provides a unique opportunity for participants to learn and discuss the current trends impacting the space and what they can expect to see in the upcoming year.”

The Innovate Next agenda will feature keynotes from Dr. Sanjay Gupta, Chief Medical Correspondent for CNN, and Sylvia Mathews Burwell, President of American University and the 22^nd Secretary of the US Department of Health and Human Services (2014 to 2017), in addition to panels and breakout sessions with change-makers from the world’s most pioneering companies and institutions. For example, one session will address rapid vaccine development and the implications for clinical trials in a post-COVID-19 world with Peter Marks, Director of the Center for Drug Evaluation and Research (CDER) division at the Food and Drug Administration (FDA), and Geoff Porges, Director of Therapeutics Research and Senior Research Analyst at SVB Leerink.

Jim Kelly, Senior Managing Director and Head of Equity Research at SVB Leerink said, “Innovate Next provides healthcare leaders a front row seat to key insights on clinical developments, regulatory changes, commercialization dynamics, and much more. The unique perspectives discussed will allow those who are developing and commercializing innovative products and services to continue to define the future of healthcare.”

Sample session topics include:

• The outcome of the 2020 election and its impact on the markets, access to healthcare, valuations, commercialization and the Affordable Care Act
• Healthcare’s K-shaped recovery post-COVID-19
• The long-term effects of the pandemic on mental health, telemedicine and alternative care
• The international landscape and market dynamics of cross-border business
• The landscape for private and public fundraising, outlook on investing and exits
• Organizational challenges and opportunities, building successful and diverse management teams and advisory boards and focusing on diversity, equity and inclusion

Attendance at Innovate Next is by invitation-only, but investors and executives may request an invite and view the agenda and speakers at events.svb.com/innovatenext.

The Innovate Next Advisory Board comprises a diverse team with some of healthcare’s most prominent founders and thought leaders. Members include:

• Anna Protopapas, CEO, Mersana
• Brad Loncar, CEO, Loncar Investments
• Christian Gormsen, CEO, Eargo
• Emily Melton, Managing Partner and Co-Founder, Threshold
• Josh Makower, General Partner, NEA
• Nate Chang, Partner, a16z
• Renee Ryan, CEO, Cala Health
• Rob Perez, Partner, General Atlantic
• Srini Akkaraju, Founding Partner, Samsara BioCapital

About SVB Financial Group

For more than 35 years, SVB Financial Group (NASDAQ: SIVB) and its subsidiaries have helped innovative companies and their investors move bold ideas forward, fast. SVB Financial Group’s businesses, including Silicon Valley Bank, offer commercial and private banking, asset management, private wealth management, brokerage and investment services and funds management services to companies in the technology, life science and healthcare, private equity and venture capital, and premium wine industries. Headquartered in Santa Clara, California, SVB Financial Group operates in centers of innovation around the world. Learn more at svb.com.

About SVB Leerink


SVB Leerink is a leading investment bank, specializing in healthcare and life sciences. The firm’s knowledge, experience and focus enable it to help its clients define and achieve their strategic, capital markets and investment objectives. SVB Leerink partners with companies that develop and commercialize innovative products and services that are defining the future of healthcare. SVB Leerink is a wholly-owned subsidiary of SVB Financial Group and is a member of FINRA/SIPC. For more information, please visit www.svbleerink.com.   

About SPD Silicon Valley Bank

Headquartered in Shanghai, China, SPD Silicon Valley Bank (SSVB) is a joint venture between Shanghai Pudong Development Bank Co., Ltd. (“SPDB” SSE: 600000) and Silicon Valley Bank (“SVB” NASDAQ: SIVB (SVB Financial Group)). SSVB is the first technology and innovation bank in China serving as an independent legal entity. It is also the first Sino-US joint venture bank. SSVB’s mission is to “increase our clients’ probability of success” by providing unique financial products and services to the technology and innovation industry and redefining the banking experience for innovation companies of all sizes. SSVB aims to create the “Innovation Ecosystem” and strives to be the most sought-after bank for China’s innovation economy. Target clients include those in the hardware, software, Internet, mobile, consumer technology, life science, biotechnology and cleantech sectors. Learn more at www.spd-svbank.com/en/.

SVB Financial Group is the holding company for all business units and groups.
SVB, SVB FINANCIAL GROUP, SILICON VALLEY BANK, MAKE NEXT HAPPEN NOW, 
硅谷
银行
, 
硅谷
银行金融集团
, and the chevron device are trademarks, separately and in combination, of SVB Financial Group in China, Hong Kong, and elsewhere, and are used under license. Silicon Valley Bank is a member of the FDIC and the Federal Reserve System. Silicon Valley Bank is the California bank subsidiary of SVB Financial Group. 

SPD, SHANGHAI PUDONG DEVELOPMENT BANK, and 
浦
发银行有限公司
 are trademarks, separately and in combination, of Shanghai Pudong Development Bank, Ltd. in China, and are used under license.

SPD Silicon Valley Bank is a Sino-U.S. joint-venture bank of Silicon Valley Bank, the California bank subsidiary and commercial banking operation of SVB Financial Group, and Shanghai Pudong Development Bank.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/innovate-next-summit-will-bring-together-global-leaders-to-explore-the-ideas-and-technologies-transforming-healthcare-301176869.html

SOURCE Silicon Valley Bank